Summary by Futu AI
KEYSTONE PHARMACEUTICAL-B WILL BE HELD ON 17 JANUARY 2024 AT THE PROVISIONAL GENERAL MEETING ON 17 JANUARY 2024 IN HALL B, 3F CONFERENCE CENTRE, 555 HAIYANG WEST ROAD, PUDONG NEW DISTRICT, SHANGHAI, CHINA. The Meeting will discuss and vote on whether to approve the share option granted to the Executive Director and Chief Executive Officer, Dr. Jian Xian Yang, which involves the subscription of a total of 14,000,000 shares at an exercise price of HK$2,350 per share. Shareholders will decide on this ordinary resolution by voting and may appoint representatives to attend and vote. Share transfer registration will be suspended from 12 to 17 January 2024 to determine the list of shareholders who are eligible to attend the general meeting and vote.